Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations.
Saved in:
| Title: | Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations. |
|---|---|
| Authors: | Timofeeva N; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Herrera B; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fujiwara H; Carna Biosciences, Inc., Kobe, Japan., Asami T; Carna Biosciences, Inc., Kobe, Japan., Endo H; Carna Biosciences, Inc., Kobe, Japan., Hatakeyama M; Carna Biosciences, Inc., Kobe, Japan., Nakajima F; Carna Biosciences, Inc., Kobe, Japan., Ohmoto H; Carna Biosciences, Inc., Kobe, Japan., Nishioka Y; Carna Biosciences, Inc., Kobe, Japan., Miyamoto K; CarnaBio USA Inc., South San Francisco, CA, USA., Arimura A; Carna Biosciences, Inc., Kobe, Japan.; CarnaBio USA Inc., South San Francisco, CA, USA., Tantawy SI; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Internal Medicine and Clinical Hematology Department, Suez Canal University, Ismailia, Egypt., Pinilla-Ibarz J; Moffitt Cancer Center, Tampa, FL, USA., Coombs CC; University of California, Irvine, CA, USA., Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sawa M; Carna Biosciences, Inc., Kobe, Japan., Gandhi V; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. vgandhi@mdanderson.org.; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. vgandhi@mdanderson.org. |
| Source: | Blood cancer journal [Blood Cancer J] 2026 May 07. Date of Electronic Publication: 2026 May 07. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 42098067 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Timofeeva+N%22">Timofeeva N</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Herrera+B%22">Herrera B</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Fujiwara+H%22">Fujiwara H</searchLink>; Carna Biosciences, Inc., Kobe, Japan.<br /><searchLink fieldCode="AU" term="%22Asami+T%22">Asami T</searchLink>; Carna Biosciences, Inc., Kobe, Japan.<br /><searchLink fieldCode="AU" term="%22Endo+H%22">Endo H</searchLink>; Carna Biosciences, Inc., Kobe, Japan.<br /><searchLink fieldCode="AU" term="%22Hatakeyama+M%22">Hatakeyama M</searchLink>; Carna Biosciences, Inc., Kobe, Japan.<br /><searchLink fieldCode="AU" term="%22Nakajima+F%22">Nakajima F</searchLink>; Carna Biosciences, Inc., Kobe, Japan.<br /><searchLink fieldCode="AU" term="%22Ohmoto+H%22">Ohmoto H</searchLink>; Carna Biosciences, Inc., Kobe, Japan.<br /><searchLink fieldCode="AU" term="%22Nishioka+Y%22">Nishioka Y</searchLink>; Carna Biosciences, Inc., Kobe, Japan.<br /><searchLink fieldCode="AU" term="%22Miyamoto+K%22">Miyamoto K</searchLink>; CarnaBio USA Inc., South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Arimura+A%22">Arimura A</searchLink>; Carna Biosciences, Inc., Kobe, Japan.; CarnaBio USA Inc., South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Tantawy+SI%22">Tantawy SI</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Internal Medicine and Clinical Hematology Department, Suez Canal University, Ismailia, Egypt.<br /><searchLink fieldCode="AU" term="%22Pinilla-Ibarz+J%22">Pinilla-Ibarz J</searchLink>; Moffitt Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Coombs+CC%22">Coombs CC</searchLink>; University of California, Irvine, CA, USA.<br /><searchLink fieldCode="AU" term="%22Jain+N%22">Jain N</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Sawa+M%22">Sawa M</searchLink>; Carna Biosciences, Inc., Kobe, Japan.<br /><searchLink fieldCode="AU" term="%22Gandhi+V%22">Gandhi V</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. vgandhi@mdanderson.org.; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. vgandhi@mdanderson.org. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101568469%22">Blood cancer journal</searchLink> [Blood Cancer J] 2026 May 07. <i>Date of Electronic Publication: </i>2026 May 07. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101568469 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2044-5385 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220445385%22">20445385 </searchLink><i>NLM ISO Abbreviation: </i>Blood Cancer J <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42098067 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/s41408-026-01509-8 Languages: – Code: eng Text: English Titles: – TitleFull: Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Timofeeva N – PersonEntity: Name: NameFull: Herrera B – PersonEntity: Name: NameFull: Fujiwara H – PersonEntity: Name: NameFull: Asami T – PersonEntity: Name: NameFull: Endo H – PersonEntity: Name: NameFull: Hatakeyama M – PersonEntity: Name: NameFull: Nakajima F – PersonEntity: Name: NameFull: Ohmoto H – PersonEntity: Name: NameFull: Nishioka Y – PersonEntity: Name: NameFull: Miyamoto K – PersonEntity: Name: NameFull: Arimura A – PersonEntity: Name: NameFull: Tantawy SI – PersonEntity: Name: NameFull: Pinilla-Ibarz J – PersonEntity: Name: NameFull: Coombs CC – PersonEntity: Name: NameFull: Jain N – PersonEntity: Name: NameFull: Sawa M – PersonEntity: Name: NameFull: Gandhi V IsPartOfRelationships: – BibEntity: Dates: – D: 07 M: 05 Text: 2026 May 07 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 2044-5385 Titles: – TitleFull: Blood cancer journal Type: main |
| ResultId | 1 |
